Mailian Medical raises $14.1 million for at-home BCI rehabilitation
The Chinese BCI startup says its $14.1 million Series B will help move non-invasive rehabilitation technology into homes and community health settings.
Zhejiang Mailian Medical Technology has completed a 100 million yuan Series B funding round, worth about $14.1 million, according to ChinaTechNews. 1 The company says the money will support the commercial expansion of its non-invasive brain-computer interface technology into clinical and home rehabilitation settings. 1
What happened
The Hangzhou-based company develops non-invasive brain-computer interface systems for neurological care and emotional-disorder management. Its products include sleep-cognition intervention platforms, brain-controlled embodied-intelligence systems and a brain-electromyography rehabilitation framework aimed at post-stroke swallowing difficulties. 1
Mailian's own website describes its L-B300 equipment as a brain-computer interface rehabilitation system that reads brain signals through an EEG cap, identifies movement intent and turns that intent into computer commands for assisted limb training. 2
The Series B round was jointly led by Chuangda Industry Control and GSR United Capital. Mailian founder Dr Cui Zhengzhe said the company plans to use the funding to develop multimodal BCI neuromodulation models and extend its hardware from hospitals towards community health centres and patients' homes. 1
Our opinion
The important detail here is not simply another startup funding headline. Mailian is pitching a shift in where rehabilitation hardware operates: away from specialist hospitals alone and towards repeatable use in community settings and at home. That ambition will depend on clinical evidence, regulatory follow-through and whether the equipment is practical for carers and patients outside a controlled setting.
The funding announcement signals expansion plans, not proof that every proposed use is already widely available. That distinction matters in a field where promising interfaces still have to earn trust through safety, accuracy and measurable rehabilitation outcomes.